Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2022-11-23 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
In connection with our earlier intimation dated November 11, 2022 regarding the Outcome of the Board Meeting for approval of the Unaudited Financial Results (Standalone and Consolidated) ....
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure of related party transactions for the half year ended September 30, 2022, submitted under Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It includes specific financial data on transactions with key management personnel, subsidiaries, and associates, including remuneration, sitting fees, rent, sales, loans, and investments. The document is addressed to the stock exchange and references an earlier intimation about unaudited financial results for the quarter and half year ended September 30, 2022. The content is focused on related party transactions disclosures rather than a full financial report or earnings release. This type of disclosure is typically part of regulatory filings to comply with listing regulations and is not an annual or interim report, earnings release, or management discussion. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a compliance disclosure document that does not fit into other specific categories like Annual Report, Interim Report, or Earnings Release.
2022-11-23 English
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Company has received information from the shareholder about ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the Corporate Relations department of BSE Limited, referencing Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the loss of share certificates by a shareholder, providing details such as folio number, certificate number, distinctive number, number of shares, and reason for loss. The document is an intimation or notification related to share certificates, specifically about loss reported by the shareholder. It does not contain financial data, audit information, management changes, or any report content. It is a regulatory compliance communication notifying the stock exchange about a shareholder's lost share certificates. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-17 English
Further to our intimation dated November 11, 2022 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and half year ....
Earnings Release Classification · 95% confidence The document is titled 'Earnings Presentation for Quarter 2 / Half Year 1 – Financial Year 2022-2023 [Q2/H1-FY23]' and contains detailed financial data including standalone and consolidated financial performance, quarterly and year-to-date results, revenue, EBITDA, PAT, EPS, and operational highlights. It is a presentation format with slides and charts summarizing the company's financial results for the quarter and half year. The document is not a brief announcement but a detailed presentation of earnings results. Therefore, it fits the definition of an Earnings Release (ER) document, which is the initial announcement of quarterly/periodical financial results with key highlights and financial data. H1 2023
2022-11-17 English
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide our letter dated November 11, ....
Regulatory Filings
2022-11-15 English
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Company has received information from the shareholder about ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to the stock exchange (BSE Limited) regarding the loss of share certificates by a shareholder. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting lost or stolen share certificates. The content is an intimation or notification about a specific event related to share certificates, not a financial report, earnings release, or management discussion. It does not contain financial data, management changes, voting results, or any other report type content. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit into more specific categories.
2022-11-15 English
We write to inform you that the Board of Directors of the Company at its meeting held on November 11, 2022 has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2022-11-11 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.